Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This study involves both the development of a novel learning tool, the Radiation Treatment Plan Evaluation Learning Module, as well as a pilot program to validate this tool as an effective resource to teach treatment plan review and optimization to radiation oncology residents.
This study involves both the development of a novel learning tool, the Radiation Treatment Plan Evaluation Learning Module, as well as a pilot program to validate this tool as an effective resource to teach treatment plan review and optimization to radiation oncology residents.
Stud procedures include screening for eligibility and completion of surveys and oncology examinations.
Participation is expected to last about 6-8 weeks.
It is expected about 20 radiation oncology resident physicians will participate in the study.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Radiation Treatment Plan Evaluation Learning Module | Experimental | Radiation oncology resident physicians will complete study procedures as below:
|
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Radiation Treatment Plan Evaluation Learning Tool | Behavioral | Web-based program comprised of a systematic, oncology treatment plan review system and learning modules. The case bank of radiation treatments plans is accessible via econtour.org. |
| Measure | Description | Time Frame |
|---|---|---|
| Objective Examination Score | Analyzed with a paired samples t-test. | Up to 8 weeks |
| Measure | Description | Time Frame |
|---|---|---|
| Oncology Resident Confidence Rate | Scored using Likert scales and analyzed with non-parametric tests. | Week 1 - 8 |
| Oncology Resident Perceived Competence Rate | Scored using Likert scales and analyzed with non-parametric tests. |
Not provided
Inclusion Criteria:
Exclusion Criteria:
-The study will not include any special populations.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Rachel Jimenez, MD | Contact | 617-726-8651 | RBJIMENEZ@PARTNERS.ORG |
| Name | Affiliation | Role |
|---|---|---|
| Rachel Jimenez, MD | Massachusetts General Hospital | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Massachusetts General Hospital Cancer Center | Boston | Massachusetts | 02215 | United States |
The Dana-Farber / Harvard Cancer Center encourages and supports the responsible and ethical sharing of data from clinical trials. De-identified participant data from the final research dataset used in the published manuscript may only be shared under the terms of a Data Use Agreement. Requests may be directed to: [contact information for Sponsor Investigator or designee]. The protocol and statistical analysis plan will be made available on Clinicaltrials.gov only as required by federal regulation or as a condition of awards and agreements supporting the research.
Data can be shared no earlier than 1 year following the date of publication
Contact the Partners Innovations team at http://www.partners.org/innovation
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Week 1 - 8 |